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 Large randomized controlled trials have demonstrated that cardiac resynchronization 
therapy (CRT) improves morbidity and mortality in patients with moderate-to-severe heart 
failure [New York Heart Association (NYHA) functional class III–IV], reduced left ventricular 
ejection fraction (LVEF ≤ 35%), and a broad QRS complex > 120 ms on optimal medical 
therapy.(1-3) As a result, the impressive survival benefit as well as the improvement in heart 
failure symptoms and quality of life observed in these trials have spurred interest in extending 
resynchronization therapy to a larger number of heart failure patients. Indeed, several lines of 
evidence indicate that currently employed guidelines (mainly based on the selection criteria used 
in the aforementioned pivotal trials) may not be perfect at identifying patients most likely to 
benefit from CRT with a significant proportion of patients being “non-responders” based on 
clinical outcomes or echocardiographic remodeling.(4) Conversely, results from various small 
studies imply that certain patient populations may benefit from CRT despite the fact that they do 
not fulfill the criteria of current CRT guidelines.(5-7) In the absence of randomized trials, data 
from large-scale “real world” surveys provide a unique opportunity to study both the current 
practice regarding the employment of a novel type of therapy as well as its efficacy and safety 
including “off-label” indications.  
In this issue of the Journal, the European CRT Survey, a joint initiative by the Heart 
Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the 
European Society of Cardiology (ESC), reports on the current European practice in the use of 
cardiac resynchronization therapy. In order to provide these information, 2438 patients from 141 
centers in 13 European countries who underwent successful implantation of a CRT device were 
followed from November 2008 until June 2009. In addition to providing a detailed description of 
patient demographics, selection criteria, and periprocedural outcomes, the survey’s data were 
further dissected according to the implanted device and age of the recipients. The authors found 
that patients receiving CRT-P (i.e., biventricular pacing device without ICD function) were 
older, less likely to present with comorbidities including ischemic heart disease or diabetes 
mellitus, and had better left ventricular function as compared to those receiving a CRT-D (i.e., 
CRT + ICD) device. Furthermore, the data demonstrate that patients older than 75 years more 
frequently had atrial fibrillation, a longer QRS duration, or concomitant comorbidities (as 
reflected by higher serum creatinine and BNP levels) as compared to those younger than 75 
years. Probably as a result of the latter (and possibly for socioeconomic reasons), older patients 
were more likely to receive CRT-P devices.  
While most of these associations do not necessarily come as a surprise and are in good 
agreement with previous trials and clinical experience, the survey does also show some 
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interesting aspects of cardiac resynchronization practice across Europe which deserves further 
attention. Most interestingly, a substantial number of patients received CRT devices for “off 
label” indications, including 9% of patients with a narrow QRS complex (<120ms) as well as 
10% with a QRS duration between 120ms and 129ms. Currently available data regarding the 
benefit of CRT in heart failure patients with a narrow QRS complex are conflicting. Using 
echocardiography-based dyssynchrony criteria, several small single center studies were able to 
identify patients with narrow QRS who responded favorably to CRT.(5, 6, 8) In contrast, the 
results of two recent randomized pilot studies (RethinQ(9) and ESTEEM-CRT) remained elusive 
due to several inherent limitations.(10) Eventually, the answer to whether CRT improves 
morbidity and mortality in this particular patient group can only be provided by an adequately 
powered, end-point driven randomized clinical trial, which is currently underway 
(Echocardiography Guided Cardiac Resynchronization Therapy – EchoCRT; NCT00683696, 
www.clinicaltrials.gov).(10) Before the results of this trial will be available, it will be of interest 
to observe the direction in which the expected one year data from the current survey will be 
pointing. Unfortunately, only qualitative assessment instead of quantitative (echocardiographic) 
parameters of LV dyssynchrony were registered for these patients, which will make further 
comprehensive analysis of this subgroup’s outcome difficult. 
Previous small trials have moreover indicated that patients with atrial fibrillation may 
profit from cardiac resynchronization therapy,(7) but evidence from large trials is lacking as this 
particular patient group was generally excluded. Controversy currently exists, however, 
regarding the necessity of AV nodal ablation, of ablation of atrial fibrillation itself, concomitant 
rate- or rhythm controlling medication and optimal device programming. In the present survey, 
23% of patients implanted were in atrial fibrillation. In view of the large proportion of heart 
failure patients with atrial fibrillation in clinical practice and the fact that data from large trials 
are scarce, further information on these parameters would have been desirable for this interesting 
subgroup. Nevertheless, outcome data after one year (possibly including this interesting 
information) will demonstrate to what extent these patients benefit in terms of clinical and 
echocardiographic improvement.  
Evidence is emerging that also patients with mildly symptomatic heart failure (i.e., 
NYHA class < III) may benefit from CRT. Indeed, data from the REVERSE trial,(11) especially 
after 24 months of CRT (presented at the Annual meeting of the American College of 
Cardiology 2009 in Orlando) as well as preliminary results from MADIT-CRT (communicated 
by Boston Scientific in June 2009 and scheduled to be presented at the ESC 2009) indicate that 
CRT improves morbidity and mortality even in patients with NYHA class I-II heart failure. In 
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the survey, 2% and 20% of the patients enrolled were indeed in NYHA functional class I and II, 
respectively. So far, however, the National Institute of Health and Clinical Excellence (NICE) 
has indicated that such patients may only be candidates for CRT if clinical deterioration has 
recently occurred. While in the overall survey population 57% of patients are reported to have 
been hospitalized for heart failure during the last year, no data are given regarding a recent 
deterioration in the subgroup of mildly symptomatic patients. Hence, a substantial proportion of 
these patients may have undergone CRT implantation on an off-label basis. In light of the above 
mentioned recent study results, this intuitive expansion of an effective therapy above and beyond 
current guidelines seems to have been a very reasonable choice. Follow-up data of the survey 
will show whether a similar response rate will also observed in this “real world” population. 
In addition to patient demographics and selection criteria, the authors also present 
periprocedural outcome data after implantation of CRT devices. In terms of efficacy, the 
majority of patients improved clinically as demonstrated by a lower NYHA class after CRT 
implantation. Electrocardiographically, the average QRS duration decreased significantly with 
biventricular pacing; no acute changes in echocardiographic parameters are reported. From a 
safety point of view, the reported perioperative complication rate was low, which may reflect the 
implanting physicians’ experience and skill over time. It may also be due to the fact, however, 
that only successful implantations were allowed to be enrolled in the survey; indeed, numbers on 
CRT eligible patients who failed or did not undergo implantation are not reported. The lack of 
stringent registration and subsequent analysis of all consecutively screened patients in whom 
CRT implantation was attempted unfortunately reduces the survey’s validity in assessing the 
safety of CRT implantation in the survey population.  
All of this notwithstanding, the present survey gives a nice and robust overview of the 
current practice regarding cardiac resynchronization therapy across a wide range of European 
centers. Planned assessment of survey patients after 1 year, including data on morbidity and 
mortality as well as echocardiographic remodeling and arrhythmias, will eagerly be awaited to 
evaluate the efficacy of CRT in this real world population. In view of the substantial number of 
patients treated with CRT for off-label indications, this will also be of interest from a 
socioeconomic point of view. From a scientific perspective, further information on less-well 
studied subpopulations (including patients with atrial fibrillation, mildly symptomatic subjects, 
and patients with a narrow QRS complex) as well as more in-depth information on technical 
subtleties such as left ventricular lead location, device programming and optimization would be 
desirable. Importantly, consecutive patient enrolment and registration, as well as critical 
evaluation of unsuccessful CRT implantation will be crucial in order to assess the safety of CRT 
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in the study population. 
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Figure: Patient selection for CRT – Present and Future 
Current indications for CRT according to current European Society of Cardiology 
(ESC) / European Heart Rhythm Association (EHRA) guidelines (12) as well as 
potential future candidates for CRT are shown. See text for details.  
A Fib: Atrial fibrillation; CHF: Congestive heart failure; LVEF: Left ventricular 
ejection fraction; NYHA: New York Heart Association.  
 
 
 
